124 related articles for article (PubMed ID: 30777652)
1. PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Knopp C; Häusler M; Müller B; Damen R; Stoppe A; Mull M; Elbracht M; Kurth I; Begemann M
Parkinsonism Relat Disord; 2019 Jun; 63():240-242. PubMed ID: 30777652
[No Abstract] [Full Text] [Related]
2. Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies.
Sturchio A; Gastaldi M; Cariddi LP; Biacchi D; Espay AJ; Franciotta D; Versino M; Mauri M
Parkinsonism Relat Disord; 2021 Jan; 82():7-9. PubMed ID: 33220521
[No Abstract] [Full Text] [Related]
3. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
4. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
5. Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans.
Hitz K; Heekeren K; Obermann C; Huber T; Juckel G; Kawohl W
Psychopharmacology (Berl); 2012 Jun; 221(3):389-96. PubMed ID: 22119935
[TBL] [Abstract][Full Text] [Related]
6. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA exacerbates amphetamine-induced dopamine depletion.
Myers CS; Witten M; Yu YL; Wagner GC
Mol Chem Neuropathol; 1998 Feb; 33(2):81-97. PubMed ID: 9565967
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
[TBL] [Abstract][Full Text] [Related]
11. [Influence of L-DOPA on rat brain depending on individual behavioral features].
Sergutina AV; Gershteĭn LM
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(12):56-9. PubMed ID: 15849866
[TBL] [Abstract][Full Text] [Related]
12. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Rinne UK; Birket-Smith E; Dupont E; Hansen E; Hyyppä M; Marttila R; Mikkelsen B; Pakkenberg H; Presthus J
J Neurol; 1975 Dec; 211(1):1-9. PubMed ID: 56427
[TBL] [Abstract][Full Text] [Related]
13. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Diggle CP; Sukoff Rizzo SJ; Popiolek M; Hinttala R; Schülke JP; Kurian MA; Carr IM; Markham AF; Bonthron DT; Watson C; Sharif SM; Reinhart V; James LC; Vanase-Frawley MA; Charych E; Allen M; Harms J; Schmidt CJ; Ng J; Pysden K; Strick C; Vieira P; Mankinen K; Kokkonen H; Kallioinen M; Sormunen R; Rinne JO; Johansson J; Alakurtti K; Huilaja L; Hurskainen T; Tasanen K; Anttila E; Marques TR; Howes O; Politis M; Fahiminiya S; Nguyen KQ; Majewski J; Uusimaa J; Sheridan E; Brandon NJ
Am J Hum Genet; 2016 Apr; 98(4):735-43. PubMed ID: 27058446
[TBL] [Abstract][Full Text] [Related]
14. TSFM mutations cause a complex hyperkinetic movement disorder with strong relief by cannabinoids.
Traschütz A; Hayer SN; Bender B; Schöls L; Biskup S; Synofzik M
Parkinsonism Relat Disord; 2019 Mar; 60():176-178. PubMed ID: 30297209
[No Abstract] [Full Text] [Related]
15. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Goodale DB; Moore KE
Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
[No Abstract] [Full Text] [Related]
16. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
[No Abstract] [Full Text] [Related]
17. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
19. Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
Okada M; Nakao R; Hosoi R; Zhang MR; Fukumura T; Suzuki K; Inoue O
J Cereb Blood Flow Metab; 2011 Jan; 31(1):124-31. PubMed ID: 20407462
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Ghika J; Gachoud JP; Gasser U
Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
